Neovacs

Neovacs ROCE

The Return on Capital Employed (ROCE) of Neovacs (ALNEV.PA) as of Oct 21, 2026 is -36.66 %. In the previous year, Return on Capital Employed (ROCE) was -14.14 % — a change of 159.23% (lower).

ROCE

-36.66 %

YoY

159.23%

Last updated:

In 2024, Neovacs's return on capital employed (ROCE) was -36.66 %, a 159.23% increase from the -14.14 % ROCE in the previous year.

The Neovacs ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2017
-1,636.41 EUR
Jan 1, 2018
-536.78 EUR
Jan 1, 2019
-289.28 EUR
Jan 1, 2020
-31.68 EUR
Jan 1, 2021
-17.83 EUR
Jan 1, 2022
-12.85 EUR
Jan 1, 2023
-14.14 EUR
Jan 1, 2024
-36.66 EUR
The Neovacs ROCE history
YEARROCEYoY
-36.66 %+159.23%
-14.14 %+10.08%
-12.85 %-27.95%
-17.83 %-43.72%
-31.68 %-89.05%
-289.28 %-46.11%
-536.78 %-67.20%
-1,636.41 %+72.24%
-950.05 %+436.51%
-177.08 %-49.07%
-347.71 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Neovacs Stock analysis

What does Neovacs do? Neovacs SA develops Kinoids, drug-candidates targeting autoimmune, inflammatory, and cancerous diseases through active immunotherapy. The company focuses on TNF-Kinoids, IFN-Kinoids, and VEGF-Kinoids for conditions like Crohn’s disease, Rheumatoid Arthritis, and lupus. Neovacs SA operates in France and the United States, with a 70% ownership stake in Neostell, a joint venture established with Stellar Biotechnologies Inc in May 2016. The firm’s revenue comes from research and development contracts, licensing agreements for its Kinoid therapies, and potential future sales of approved treatments. Neovacs SA targets pharmaceutical companies and research institutions seeking innovative immunotherapy solutions. Its primary customers include biotechnology firms interested in developing new treatments for autoimmune and inflammatory diseases. The company’s portfolio of Kinoids, including TNF-Kinoids for Crohn’s disease and Rheumatoid Arthritis, appeals to partners looking to expand their therapeutic offerings. Neostell, the 70% owned joint venture, further supports the company’s strategy by enhancing its research and development capabilities. The company’s business model relies on the development of Kinoids as drug-candidates, which are designed to induce antibody responses in patients. By focusing on specific disease targets like TNF, IFN, and VEGF pathways, Neovacs SA positions itself as a specialized provider in immunotherapy. Its operations span France and the United States, with a dedicated team of 24 full-time employees driving research efforts. The joint venture with Stellar Biotechnologies Inc strengthens its market presence and expands its pipeline of potential treatments. Neovacs is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Neovacs's Return on Capital Employed (ROCE)

Neovacs's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Neovacs's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Neovacs's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Neovacs’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Neovacs stock

Return on Capital Employed (ROCE) of Neovacs is -36.66 % in 2024.

Return on Capital Employed (ROCE) of Neovacs changed from -14.14 % to -36.66 %, representing a 159.23% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Neovacs since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Neovacs with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Neovacs

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Neovacs